What is Harrow Health, Inc. (HROW)?

Harrow Health, Inc. (HROW) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of HROW?

The current price of HROW is $29.07. Prices are updated in real time on Stocks360.

What is HROW's price-to-earnings (PE) ratio?

HROW's trailing twelve-month PE ratio is -29.29, based on current price and earnings per share data available on Stocks360.

What is HROW's market capitalization?

HROW's market capitalization is $1,089,771,800.00, placing it in the small-cap tier.

Harrow Health, Inc. (HROW)

Stock analysis · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$29.07

Market Cap

$1.09B

PE (TTM)

-29.29

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.24

Day Range

$28.49 – $29.57

52-wk Range

$26.96 – $54.85

Avg Volume

N/A

Volume

635.44K

Harrow Health, Inc. (HROW) is a publicly traded company in the Healthcare sector. Latest price: $29.07. Market cap $1.09B. Trailing PE -29.29. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 6 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-28 · $38.15 2026-10-27 · $29.07 (-23.80%)

Earnings

Most Recent

Aug 10, 2026

EPS $-0.46 vs est. $-0.18

Missed by $0.28

Next Earnings

Nov 9, 2026

EPS estimate $0.17

Proprietary Signals

Signal snapshot temporarily unavailable.

About Harrow Health, Inc.

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several pharmaceutical ventures. These encompass Surface Ophthalmics, Inc., a clinical-stage firm actively developing and commercializing therapeutic agents for ocular surface diseases; Melt Pharmaceuticals, Inc., another clinical-stage entity concentrating on proprietary non-intravenous sedation and anesthesia treatments for various medical procedures conducted in hospital, outpatient, and office environments; and Eton Pharmaceuticals, Inc., a commercial-stage company involved in the creation and market launch of drug products. Moreover, Harrow Health holds royalty interests in four investigational drug candidates currently being advanced by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company, initially incorporated in 2006 and based in San Diego, California, underwent a name change…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-29.29×
P/S (TTM)	3.95×
P/B	71.43×
PEG	0.54×
P/FCF (TTM)	191.66×
EV / EBITDA	116.80×
EV / Sales	4.74×
Earnings Yield	-3.43%
Free Cash Flow Yield	0.52%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.31B
Revenue (TTM)	$275.59M
Net Income (TTM)	-$37.36M
Free Cash Flow (TTM)	$31.13M
Net Debt	$216.85M
Working Capital	$127.14M
Gross Margin	73.28%
Operating Margin	2.07%
Net Margin	-13.51%
Return on Equity	-103.86%
Return on Invested Capital	1.81%